AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8529780 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg on day 1 followed by 100 mg daily or 200 mg daily
Number of subjects: 210
Study 8529780 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav 500 mg three times daily
Number of subjects: 210
Study 8529780 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossed over to alternative antibiotic
Number of subjects: 210
Study 8529780 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 210
Study 8529780 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 210
Study 2325052 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol with indomethacin
Number of subjects: 10
Study 2325052 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 10
Study 2325052 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol plus indomethacin
Number of subjects: 10
Study 220656 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (30 mg, s.c.)
Number of subjects: 18
Study 220656 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 18
Study 31512746 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 0
Study 31512746 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 0
Study 30478131 — intervention group
Group type: EXPERIMENTAL
Intervention: Namaste Care intervention delivered at nursing care home level
Number of subjects: 0
Study 30478131 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 27562137 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic prednisone, etoposide, and cyclophosphamide
Number of subjects: 44
Study 27562137 — intervention group
Group type: COMPARATOR
Intervention: Conventional salvage chemotherapy
Number of subjects: 44
Study 26591359 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XC), three pills each time, three times daily for two therapeutic courses (one month each).
Number of subjects: 180
Study 26591359 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate Tablet, four tablets each time, once per week for two therapeutic courses (one month each).
Number of subjects: 180
Study 26591359 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (60 patients), no intervention specified.
Number of subjects: 180
Study 26591359 — intervention group
Group type: COMPARATOR
Intervention: Xinfeng Capsule (XC) vs Methotrexate Tablet after treatment.
Number of subjects: 180
Study 23064844 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-site strength-training program
Number of subjects: 427
Study 23064844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 427
Study 20103757 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 167
Study 20103757 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (ADT)
Number of subjects: 167
Study 18771543 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 28
Study 18771543 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPAP therapy)
Number of subjects: 28
Study 16299866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (1 mg/dose)
Number of subjects: 67
Study 16299866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 16299866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide
Number of subjects: 67
Study 12297769 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative endoscopic biliary stent placement
Number of subjects: 337
Study 12297769 — intervention group
Group type: COMPARATOR
Intervention: No endoscopic biliary stent placement (control)
Number of subjects: 337
Study 10327029 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin 100 mg/m2 plus cisplatin 75 mg/m2 q 4 weeks
Number of subjects: 210
Study 10327029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 500 mg/m2 plus epirubicin 75 mg/m2 plus cisplatin 50 mg/m2 q 4 weeks
Number of subjects: 210
Study 8536451 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexiGard
Number of subjects: 4286
Study 8536451 — intervention group
Group type: COMPARATOR
Intervention: TCu 380A
Number of subjects: 4286
Study 1827613 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of etodolac twice daily
Number of subjects: 39
Study 1827613 — intervention group
Group type: COMPARATOR
Intervention: 500 mg of naproxen twice daily
Number of subjects: 39
Study 7028941 — intervention group
Group type: EXPERIMENTAL
Intervention: surgical pocket elimination or reduction
Number of subjects: 90
Study 7028941 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Widman flap surgery
Number of subjects: 90
Study 7028941 — intervention group
Group type: EXPERIMENTAL
Intervention: subgingival curettage
Number of subjects: 90
Study 7028941 — intervention group
Group type: EXPERIMENTAL
Intervention: scaling and root planing only
Number of subjects: 90
Study 30276598 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindset intervention
Number of subjects: 598
Study 30276598 — intervention group
Group type: COMPARATOR
Intervention: Control activities
Number of subjects: 598
Study 28672273 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-administered early intervention program
Number of subjects: 130
Study 28672273 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study 25917876 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 1103
Study 25917876 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 1103
Study 23377369 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified staircase method
Number of subjects: 0
Study 23377369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending 3-alternative forced-choice method
Number of subjects: 0
Study 23377369 — intervention group
Group type: COMPARATOR
Intervention: Both methods
Number of subjects: 0
Study 21271357 — intervention group
Group type: EXPERIMENTAL
Intervention: Be Under Your Own Influence
Number of subjects: 0
Study 21271357 — intervention group
Group type: COMPARATOR
Intervention: Above the Influence
Number of subjects: 0
Study 19899578 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 25
Study 19899578 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 25
Study 17285571 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments for GERD
Number of subjects: 6
Study 17285571 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical models
Number of subjects: 6
Study 17285571 — intervention group
Group type: EXPERIMENTAL
Intervention: Models for absolute treatment effects
Number of subjects: 6
Study 15132728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg once daily)
Number of subjects: 31
Study 15132728 — intervention group
Group type: COMPARATOR
Intervention: Oestradiol valerate (2 mg daily) and dydrogesterone (20 mg daily for 2 weeks every 3 months)
Number of subjects: 31
Study 11490695 — intervention group
Group type: EXPERIMENTAL
Intervention: Automix light viscosity material
Number of subjects: 100
Study 11490695 — intervention group
Group type: EXPERIMENTAL
Intervention: Automix regular viscosity material
Number of subjects: 100
Study 11490695 — intervention group
Group type: COMPARATOR
Intervention: Tubed light viscosity material
Number of subjects: 100
Study 11490695 — intervention group
Group type: COMPARATOR
Intervention: Tubed regular viscosity material
Number of subjects: 100
Study 9589508 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support (number of persons in support system)
Number of subjects: 102
Study 9589508 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive social contact
Number of subjects: 102
Study 9589508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 102
Study 8026230 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemicolectomy
Number of subjects: 270
Study 8026230 — intervention group
Group type: COMPARATOR
Intervention: Left segmental colectomy
Number of subjects: 270
Study 2777438 — intervention group
Group type: EXPERIMENTAL
Intervention: n.100 m
Number of subjects: 11
Study 2777438 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.100 m
Number of subjects: 11
Study 2777438 — intervention group
Group type: EXPERIMENTAL
Intervention: n.300 m
Number of subjects: 11
Study 2777438 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.400 m
Number of subjects: 11
Study 2777438 — intervention group
Group type: COMPARATOR
Intervention: n.300 m and 2.400 m
Number of subjects: 11
Study 1108176 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 36
Study 1108176 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline hydrochloride
Number of subjects: 36
Study 31178152 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month trastuzumab treatment (loading dose of 8 mg/kg followed by maintenance doses of 6 mg/kg)
Number of subjects: 4089
Study 31178152 — intervention group
Group type: COMPARATOR
Intervention: 12-month trastuzumab treatment (loading dose of 8 mg/kg followed by maintenance doses of 6 mg/kg)
Number of subjects: 4089
Study 31178152 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month trastuzumab treatment
Number of subjects: 4089
Study 31178152 — intervention group
Group type: COMPARATOR
Intervention: 12-month trastuzumab treatment
Number of subjects: 4089
Study 28345809 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily
Number of subjects: 0
Study 28345809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25894275 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic information
Number of subjects: 200
Study 25894275 — intervention group
Group type: COMPARATOR
Intervention: Behavioral information
Number of subjects: 200
Study 25894275 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive communication approach
Number of subjects: 200
Study 25894275 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive communication approach
Number of subjects: 200
Study 22608115 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy (ICBT)
Number of subjects: 81
Study 22608115 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition (CC)
Number of subjects: 81
Study 20629665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid infusion
Number of subjects: 56
Study 20629665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18637755 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-day famciclovir (1000 mg administered twice daily)
Number of subjects: 1179
Study 18637755 — intervention group
Group type: COMPARATOR
Intervention: 3-day valacyclovir (500 mg administered twice daily)
Number of subjects: 1179
Study 18637755 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-day famciclovir
Number of subjects: 1179
Study 18637755 — intervention group
Group type: COMPARATOR
Intervention: 3-day valacyclovir
Number of subjects: 1179
Study 17039234 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (alloSCT)
Number of subjects: 58
Study 17039234 — intervention group
Group type: COMPARATOR
Intervention: Autologous stem cell transplantation (autoSCT)
Number of subjects: 58
Study 17039234 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 58
Study 12953944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of benzoyl peroxide 6% cleanser and tretinoin 0.1% microsphere gel
Number of subjects: 87
Study 12953944 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.1% microsphere gel (monotherapy)
Number of subjects: 87
Study 12953944 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 87
Study 10994910 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exercise (50 biceps curls with a 5-lb dumbbell)
Number of subjects: 26
Study 10994910 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization (arm casted and supported in a sling at 90 degrees)
Number of subjects: 26
Study 10994910 — intervention group
Group type: COMPARATOR
Intervention: Control (no restriction of arm activity)
Number of subjects: 26
Study 8836273 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 micrograms kg-1 clonidine
Number of subjects: 60
Study 8836273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study 8836273 — intervention group
Group type: COMPARATOR
Intervention: 2 micrograms kg-1 clonidine
Number of subjects: 60
Study 1442855 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 48
Study 1442855 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 48
Study 1442855 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 48
Study 1442855 — intervention group
Group type: COMPARATOR
Intervention: Diuretic
Number of subjects: 48
Study 3971296 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump therapy
Number of subjects: 65
Study 3971296 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection plus pump
Number of subjects: 65
Study 3971296 — intervention group
Group type: COMPARATOR
Intervention: Pump only
Number of subjects: 65
Study 3971296 — intervention group
Group type: COMPARATOR
Intervention: Resection of metastases
Number of subjects: 65
Study 3971296 — intervention group
Group type: COMPARATOR
Intervention: Unresectable disease with positive portal nodes
Number of subjects: 65
Study 30140899 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuretic peptides (log-transformed and standardized, expressed per 1 SD, z score)
Number of subjects: 1057
Study 26808146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure stimulation (120% PPT) for 5 seconds
Number of subjects: 20
Study 26808146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure stimulation (120% PPT) for 60 seconds
Number of subjects: 20
Study 26808146 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-induced pain
Number of subjects: 20
Study 26808146 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed onset muscle soreness (eccentric exercise)
Number of subjects: 20
Study 26808146 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 2 assessments compared to Day 1
Number of subjects: 20
Study 24699551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary Adenosine (100 µg/stented vessel)
Number of subjects: 100
Study 24699551 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 100
Study 22040605 — intervention group
Group type: COMPARATOR
Intervention: Living-room theatre activity by professional actors (E2)
Number of subjects: 131
Study 22040605 — intervention group
Group type: EXPERIMENTAL
Intervention: Living-room theatre activity by trained professional caregivers (E1)
Number of subjects: 131
Study 22040605 — intervention group
Group type: COMPARATOR
Intervention: Usual reminiscence group activity (Control)
Number of subjects: 131
Study 20353387 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype (GT) test
Number of subjects: 246
Study 20353387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phenotype-genotype test (PGT)
Number of subjects: 246
Study 20353387 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir
Number of subjects: 246
Study 20353387 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir
Number of subjects: 246
Study 20353387 — intervention group
Group type: EXPERIMENTAL
Intervention: Other PIs
Number of subjects: 246
Study 20353387 — intervention group
Group type: EXPERIMENTAL
Intervention: New regimen with two or more active agents
Number of subjects: 246
Study 17506739 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq device
Number of subjects: 7
Study 17506739 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy with Macintosh blade
Number of subjects: 7
Study 15837451 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-cyclooxygenase-2 non-steroidal anti-inflammatory drugs (anti-COX-2 NSAIDs)
Number of subjects: 212
Study 15837451 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of daily tablets of study medication
Number of subjects: 212
Study 15837451 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of clinical visits
Number of subjects: 212
Study 11913886 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol + brimonidine
Number of subjects: 20
Study 11913886 — intervention group
Group type: COMPARATOR
Intervention: timolol + placebo
Number of subjects: 20
Study 9466539 — intervention group
Group type: EXPERIMENTAL
Intervention: PFP-2 vaccine
Number of subjects: 21
Study 9466539 — intervention group
Group type: COMPARATOR
Intervention: Placebo (influenza vaccine)
Number of subjects: 21
Study 7622989 — intervention group
Group type: EXPERIMENTAL
Intervention: Elicited imitation with verbal elaboration opportunity
Number of subjects: 12
Study 7622989 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal measures
Number of subjects: 12
Study 2497130 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (10 mg, im)
Number of subjects: 16
Study 2497130 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (10 or 100 mg, orally)
Number of subjects: 16
Study 2497130 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 19188 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium (15 mg) with antacid suspension
Number of subjects: 15
Study 19188 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate dipotassium (15 mg) alone
Number of subjects: 15
Study 7246998 — intervention group
Group type: EXPERIMENTAL
Intervention: Brevimytal (premedicated group)
Number of subjects: 139
Study 7246998 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapanal (premedicated group)
Number of subjects: 139
Study 7246998 — intervention group
Group type: COMPARATOR
Intervention: Halothane (inhalational agent)
Number of subjects: 139
Study 7246998 — intervention group
Group type: COMPARATOR
Intervention: Enflurane (inhalational agent)
Number of subjects: 139
Study 7246998 — intervention group
Group type: COMPARATOR
Intervention: No premedication (Trapanal or Brevimytal)
Number of subjects: 139
Study 31800053 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher nicotine option (cigarettes ≥ 5.3 mg/g)
Number of subjects: 101
Study 31800053 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (2.5 µg/kg)
Number of subjects: 101
Study 31800053 — intervention group
Group type: COMPARATOR
Intervention: Very low or no nicotine option (cigarettes ≤ 2.3 mg/g and placebo spray)
Number of subjects: 101
Study 29513683 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app (DiaSocial)
Number of subjects: 27
Study 26874820 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional carbon-dioxide laser-assisted topical therapy with terbinafine cream (once-daily for 3 months)
Number of subjects: 75
Study 26874820 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional carbon-dioxide laser-assisted topical therapy
Number of subjects: 75
Study 24954487 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐tourniquet group
Number of subjects: 70
Study 24954487 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet group
Number of subjects: 70
Study 24954487 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 22424623 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 209
Study 22424623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 209
Study 19091806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 81
Study 19091806 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 81
Study 17991660 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine (20 g ethanol/d for 4 weeks)
Number of subjects: 35
Study 17991660 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (20 g ethanol/d for 4 weeks)
Number of subjects: 35
Study 16192580 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 80 mg/m2 IV on day 1 alone (arm A)
Number of subjects: 250
Study 16192580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 IV on day 1 combined with raltitrexed 3 mg/m2 (arm B)
Number of subjects: 250
Study 16192580 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone (arm A)
Number of subjects: 250
Study 16192580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin combined with raltitrexed (arm B)
Number of subjects: 250
Study 16192580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with raltitrexed (arm B)
Number of subjects: 250
Study 11960042 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analog and iron plus tibolone (group A)
Number of subjects: 66
Study 11960042 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 66
Study 11960042 — intervention group
Group type: COMPARATOR
Intervention: Only iron (group C)
Number of subjects: 66
Study 9821415 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 800 micrograms once daily
Number of subjects: 24
Study 9821415 — intervention group
Group type: COMPARATOR
Intervention: Inhaled budesonide 400 micrograms twice daily
Number of subjects: 24
Study 7666812 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day regimen of estradiol valerate (EV) opposed with cyproterone acetate (CPA)
Number of subjects: 38
Study 7666812 — intervention group
Group type: COMPARATOR
Intervention: 28-day regimen of conjugated equine estrogens (CEE) with norgestrel (NG)
Number of subjects: 38
Study 2680179 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% minoxidil
Number of subjects: 47
Study 2680179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 340306 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (50 mg twice daily)
Number of subjects: 20
Study 340306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31308630 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet form of mycophenolate mofetil (500 mg)
Number of subjects: 116
Study 31308630 — intervention group
Group type: COMPARATOR
Intervention: Capsule form of mycophenolate mofetil (250 mg)
Number of subjects: 116